CytoDyn Inc.

CytoDyn Inc. is a clinical-stage biotechnology company focused on developing treatments for multiple therapeutic indications. Its primary asset is leronlimab, a novel humanized monoclonal antibody that targets the C-C chemokine receptor type 5 (CCR5) receptor. The company is investigating leronlimab in various areas, including COVID-19, where it has been studied for its potential to modulate the immune response. In oncology, leronlimab is under phase 2 development for micro-satellite stable colorectal cancer and solid tumors such as metastatic triple-negative breast cancer. CytoDyn also has a collaboration with Creatv Bio. The company was formerly known as RexRay Corporation and was incorporated in 2002.

CytoDyn Inc. is listed on the OTC Markets OTCQB exchange under the ticker symbol CYDY. The OTCQB is a venture market for early-stage and developing U.S. and international companies. Trading is conducted in U.S. dollars (USD), which is the company's reporting currency. As an over-the-counter listing, shares are traded through broker-dealers rather than on a centralized exchange like the NYSE or Nasdaq. Investors should be aware that OTC markets may have lower liquidity and different regulatory requirements compared to major exchanges.

CytoDyn Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, it focuses on researching and developing new drugs and therapies, particularly in the areas of immunology and oncology. The company's lead candidate, leronlimab, is a monoclonal antibody designed to target the CCR5 receptor, which plays a role in immune regulation and cancer progression. Being in the clinical stage, CytoDyn has not yet commercialized any products and is primarily engaged in clinical trials to demonstrate safety and efficacy.

CytoDyn Inc. is headquartered in Vancouver, Washington, United States. The company serves the U.S. market primarily, as its clinical trials and regulatory activities are focused on the United States. However, as a biotechnology company developing treatments for global health issues like COVID-19 and cancer, its potential market could be worldwide if its therapies receive regulatory approval. The company's collaboration with Creatv Bio may also expand its research capabilities. CytoDyn was incorporated in 2002 and has been operating as a clinical-stage entity since then.

As a clinical-stage biotechnology company, CytoDyn Inc. does not currently generate revenue from product sales, as its lead candidate leronlimab has not yet received regulatory approval for commercialization. The company's business model focuses on advancing leronlimab through clinical trials for multiple indications, including COVID-19, colorectal cancer, and triple-negative breast cancer. CytoDyn may generate revenue in the future through licensing agreements, partnerships, or direct sales if leronlimab is approved. Currently, the company funds its operations through equity offerings and other financing activities. Its collaboration with Creatv Bio may also provide research support.